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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a homotetrameric enzyme involved in a key step
of glycolysis, also has a role in mediating cell death under nitrosative stress. Our previous reports suggest
that nitric oxide-induced intramolecular disulﬁde-bonding GAPDH aggregation, which occurs through
oxidation of the active site cysteine (Cys-152), participates in a mechanism to account for nitric oxide-
induced death signaling in some neurodegenerative/neuropsychiatric disorders. Here, we demonstrate
a rescue strategy for nitric oxide-induced cell death accompanied by GAPDH aggregation in a mutant
with a substitution of Cys-152 to alanine (C152A-GAPDH). Pre-incubation of puriﬁed wild-type GAPDH
with C152A-GAPDH under exposure to nitric oxide inhibited wild-type GAPDH aggregation in a
concentration-dependent manner in vitro. Several lines of structural analysis revealed that C152A-
GAPDH extensively interfered with nitric oxide-induced GAPDH-amyloidogenesis. Overexpression of
doxycycline-inducible C152A-GAPDH in SH-SY5Y neuroblastoma signiﬁcantly rescued nitric oxide-
induced death, concomitant with the decreased formation of GAPDH aggregates. Further, both co-
immunoprecipitation assays and simulation models revealed a heterotetramer composed of one dimer
each of wild-type GAPDH and C152A-GAPDH. These results suggest that the C152A-GAPDH mutant acts
as a dominant-negative molecule against GAPDH aggregation via the formation of this GAPDH hetero-
tetramer. This study may contribute to a new therapeutic approach utilizing C152A-GAPDH against brain
damage in nitrosative stress-related disorders.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In addition to its role in glycolysis, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) is a multifunctional enzyme that is also
involved in nitrosative stress-induced cell death [1]. There are two
main pathways of GAPDH-mediated cell death [2]. First, GAPDH
nuclear translocation under conditions of nitrosative stress such as, atomic force microscopy;
hyde-3-phosphate dehydro-





Inc. This is an open access article ua nitric oxide donor s-nirosoglutathione promotes the expression of
several apoptosis-related genes such as p53 upregulatedmodulator
of apoptosis (PUMA) and Bcl2-associated X protein (BAX) [3,4].
Second, GAPDH aggregation induced by oxidative/nitrosative stress
is likely to trigger cellular dysfunction accompanied with energy
depletion both in vitro and in vivo [5e7].
In several neurological disorders that occur under oxidative/
nitrosative stress in the brain, the accumulation of protein aggre-
gation and the subsequent increase in aberrant aggregates promote
the formation of pathological deposits (usually termed amyloids),
leading to the causality of these diseases [8]. Some reports indicate
that insoluble GAPDH aggregation occurs in pathological amyloidal
deposits, including senile plaques and neuroﬁbrillary tangles in
Alzheimer's disease [9], and Lewy bodies in Parkinson's disease
[10]. Further, massive production of nitric oxide in the brain is likely
to play a critical role in the pathogenesis [11,12]. From thesender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Cys-152) plays an essential role in nitric oxide-induced disulﬁde-
bonding amyloid-like GAPDH aggregation: a mutant with a sub-
stitution of Cys-152 to alanine (C152A-GAPDH) fails to aggregate
even in the presence of nitrosative stress [5e7]. Additionally, it has
been reported that GAPDH is structurally altered in associationwith
nitrosative stress in brain damage [13,14]. Thus, abnormal changes
in GAPDH structure seem to play a critical role in the pathogenesis
of these diseases related to excessive emergence of nitric oxide [15].
A high-resolution structure of human GAPDH has been pub-
lished [16]. Human GAPDH is an asymmetric homotetramer con-
sisting of a dimer of dimers with speciﬁc dimerization domains
[16,17]. Also, heteromeric hybridization can easily occur among
dimers of GAPDH derived from various species [18,19]. Further, the
oligomeric status of the GAPDH-C152A mutant is completely
similar to that of wild-type GAPDH [7]: GAPDH exists as an equi-
librium mixture of tetramers, dimers, and monomers [20]. These
ﬁndings lead us to hypothesize that C152A-GAPDHmight be able to
interfere with wild-type GAPDH aggregation induced by nitric ox-
ide and might therefore provide a novel therapeutic for nitric oxide
induced-GAPDH aggregation-related neurodegenerative/neuro-
psychiatric disorders.
Here, we report that C152A-GAPDH acts as a dominant-negative
mutant protecting against GAPDH aggregation-induced cell death
in SH-SY5Y neuroblastoma under nitrosative stress, through the
formation of a heterotetramer between wild-type GAPDH and
C152A-GAPDH. The therapeutic implications utilizing this mutant
in vivo are discussed.
2. Materials and methods
2.1. Chemicals, antibodies, and plasmids
Unless otherwise noted, chemicals were of analytical grade.
Mouse anti-GAPDH monoclonal antibody (MAB374) was obtained
from Millipore Japan (Tokyo, Japan); rabbit anti-GAPDH polyclonal
antibody (ab9485) was obtained from Abcam (Cambridge, MA);
rabbit polyclonal anti-Myc antibody (A-14: sc-789) and rabbit
polyclonal anti-His antibody (Omni-probe, M-21: sc-499) were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA); mouse
anti- b-actin monoclonal antibody was obtained from Sigma-
eAldrich Japan (Tokyo, Japan). Human wild type- (WT-) GAPDH
cDNA was generated as reported previously [7]. For bacterial
expression, cDNAwas cloned into pBAD-HisA (Invitrogen, Carlsbad,
CA) using the SacI-KpnI sites. For mammalian cell line expression,
the cDNAwas cloned into pcDNA4-TO-Myc/HisA (Invitrogen) using
the EcoRI-EcoRV sites. The alanine-substituted mutant C152A-
GAPDH was generated using the QuikChange site-directed muta-
genesis kit with WT-GAPDH as the template, according to the
manufacturer's protocol (Stratagene, La Jolla, CA), as reported pre-
viously [7].
2.2. Expression and puriﬁcation of recombinant GAPDH
The pBAD-HisA vector carryingWT- or C152A-GAPDH cDNAwas
transformed into gap () Escherichia coli strain W3CG [21].
Expression and puriﬁcation of these recombinant GAPDH proteins
were carried out as described previously [5,7]. Protein concentra-
tions were determined spectrophotometrically assuming a ε0.1% of
1.0 at 280 nm.
2.3. In vitro aggregation assay
The in vitro aggregation assay for puriﬁed proteins was per-
formed basically according to published methods [5,7]. PuriﬁedHis-taggedWT-GAPDH (0.3mg/ml) with His-tagged C152A-GAPDH
(0.3, 0.5, or 0.75 mg/ml) were mixed with or without pre-
incubation for 24 h at 4 C, and then the mixtures were treated
with 100 mM NOR3 (a NO generator, DOJINDO, Kumamoto, Japan)
for 24 h at 37 C. To measure the turbidity of the solutions, the
absorbance at 405 nmwas recorded using a VERSA Max microplate
reader (Molecular Devices Japan, Tokyo, Japan). Alternatively, the
turbidities of puriﬁed His-tagged WT-GAPDH (0.3 mg/ml) with
alcohol dehydrogenase (ADH, 0.83 mg/ml, SigmaeAldrich Japan,
Tokyo, Japan), malate dehydrogenase (MDH, 0.69 mg/ml, Roche
Diagnostics, Basel, Switzerland), or aldolase (ALD, 0.79 mg/ml,
Roche Diagnostics) weremeasured as a same condition as the assay
using C152A-GAPDH (0.75 mg/ml). The each gram concentration of
ADH (Mw ¼ 40 kDa), MDH (Mw ¼ 33 kDa), or ALD (Mw ¼ 38 kDa)
was determined as equal to the same molar concentration of
C152A-GAPDH (Mw ¼ 36 kDa). The turbidities of puriﬁed His-
tagged WT-GAPDH (0.3 mg/ml) with glyceraldehyde-3-phosphate
(GAP, 2 mM) or glutathione (GSH, 1, 3, or 10 mM) were measured
as described above.
2.4. In vitro GAPDH hybridization
Puriﬁed erythrocyte human GAPDH (0.3 mg/ml, SigmaeAldrich
Japan) and His-tagged C152A-GAPDH (0.3, 0.6, or 0.75 mg/ml) were
mixed and incubated in G20 buffer containing 50 mM TriseHCl
(pH ¼ 8.0), 150 mM NaCl, 1 mM EDTA, and 5% glycerol for 24 h at
4 C. Then, samples (500 ml) were subjected to an in vitro immu-
noprecipitation assay using both anti-His polyclonal antibody
(1 mg/assay) and protein-G sepharose (GE Healthcare Japan, Tokyo,
Japan) according to published biochemical protocols [22]. Hybrid-
ization between native GAPDH and His-tagged recombinant
GAPDH was analyzed by 5e20% SDS-PAGE, and each protein was
stained with 0.5% (w/v) Coomassie brilliant blue. The intensity of
the bands was measured using Scion image software ver. 4.0.3.2.
(Scion Corporation, Frederick, MD).
2.5. Analyses of amyloid-like aggregation of GAPDH
PuriﬁedWT-GAPDH (0.3 mg/ml) without or with C152A-GAPDH
(0.75 mg/ml) was treated with NOR3 (100 mM) for 24 h, and sub-
jected to following analyses. Thioﬂavin-T ﬂuorescence: Seventy
microliters of each sample mixture were added to 2 ml of
Thioﬂavin-T solution (10 mM in 50 mM glycine buffer, pH 8.0, Sig-
maeAldrich Japan), and the ﬂuorescence intensities were
measured at 450 nm excitation and 482 nm emission wavelengths
using an F-2000 ﬂuorescence spectrophotometer (Hitachi, Tokyo,
Japan). Congo Red spectral: Congo Red (2.5 mM, SigmaeAldrich
Japan) was added to the mixture, and incubated for 30 min in the
dark. Subsequently, the absorbance of mixtures (wavelength from
400 nm to 600 nm) was scanned using an U3210 spectrophotom-
eter (Hitachi). Atomic Force Microscopy (AFM): The sample mix-
tures were spotted onto fresh cleaved mica, incubated for 1 min,
rinsed three times with water, and then dried. All measurements
were carried out in ‘‘tapping mode’’ under ambient conditions with
single-beam silicon cantilever probes. Three regions of the mica
surface were examined to ensure that an accurate sample of the
structures on the mica was obtained [23].
2.6. Cell culture and biochemical analysis
Human neuroblastoma SH-SY5Y cells (American Type Culture
Collection, ATCC, Manassas, VA) were grown in Dulbecco's modi-
ﬁed Eagle medium/Ham's F12 Medium (DMEM/F12) supplemented
with 10% fetal bovine serum, 2 mM glutamine, and anti-
bioticseantimycotics (Invitrogen) at 37 C in a 5% CO2 humidiﬁed
Fig. 1. C152A-GAPDH inhibits NO-induced GAPDH aggregation. The concentration-dependent effect of C152A-GAPDH on the formation of NOR3-induced GAPDH aggregates is
shown. Mixtures of His-tagged WT-GAPDH (0.3 mg/ml) and C152A-GAPDH (0, 0.3, 0.5, or 0.75 mg/ml), without (left panel) or with (right panel) pre-incubation, were incubated at
37 C for the indicated time periods with NOR3 (100 mM) treatment, and the turbidity of the solutions was measured in terms of absorbance at 405 nm. (n ¼ 4, **, p < 0.01).
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expression of GAPDH has been established as reported previously
[7]. Subcellular fractionation was carried out according to the
following procedures. After 48-h treatment with either control
vehicle (0.1 N NaOH) or a NO generator NOC18 (DOJINDO), cells
were washed twice with phosphate-buffered saline (PBS) and then
incubated for 5 min in ice-cold PBS containing 40 mM iodoaceta-
mide to protect unmodiﬁed thiols from oxidation during fraction-
ation. All subsequent steps were performed at 4 C. Cells wereFig. 2. C152A-GAPDH hybridizes with WT-GAPDH. (A) Hybrid formation of native (corresp
GAPDH (0.3 mg/mL) and C152A-GAPDH (0 or 0.75 mg/mL) were mixed and incubated at 4 C
and subjected to 5e20% SDS-PAGE (n ¼ 3). (B) The stoichiometry of hybrid formation betwe
shown (n ¼ 4). The regression line and correlation coefﬁcient (R2) in right panel are calculscraped into 500 ml of buffer A containing 10 mM TriseHCl (pH 7.5),
10 mM NaCl, 3 mM MgCl2, 0.05% Nonidet P-40, 0.5% Triton-X100,
40 mM iodoacetamide, 1 mM phenylmethylsulfonyl ﬂuoride
(PMSF), and protease inhibitor mixture (Roche Diagnostics). After
30 min, the cell suspension was homogenized vigorously for 15 s
with rocking. The total lysate was centrifuged at 20400  g for
10 min, and the pellet was collected to prepare the insoluble frac-
tion. To assess GAPDH hybridization in cells, the puriﬁed lysates
were subjected to an immunoprecipitation assay using both anti-onding to WT-GAPDH) and His-tagged C152A-GAPDH is shown. Puriﬁed human native
for 24 h. These solutions were immunoprecipitated with anti-His polyclonal antibody,
en WT-GAPDH (native form, 0.3 mg/ml) and C152A-GAPDH (0.3, 0.6, or 0.75 mg/ml) is
ated by GraphPad Prism.
Fig. 3. Effects of other cysteine-containing glycolytic enzymes, glyceraldehyde-3-phosphate (GAP), or glutathione (GSH) on NO-induced GAPDH aggregation. (A) The effect of
alcohol dehydrogenase (ADH), malate dehydrogenase (MDH), or aldolase (ALD) on NOR3-induced GAPDH aggregate formation is shown. Mixtures of WT-GAPDH (0.3 mg/mL) and
ADH (0 or 0.83 mg/mL), MDH (0 or 0.69 mg/mL), or ALD (0 or 0.79 mg/mL), were incubated at 37 C for 24 h under NOR3 (100 mM) treatment, and the turbidity of these solutions
was measured in terms of absorbance at 405 nm (n ¼ 4). (B) The effect of GAP at 2 mM on NOR3-induced GAPDH aggregate formation is shown. (n ¼ 4) (C) The effect of GSH at 1, 3,
or 10 mM on NOR3-induced GAPDH aggregate formation is shown. (n ¼ 4, **, p < 0.01).
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Healthcare Japan, Tokyo, Japan) according to published biochemical
protocols [22]. The ratio of hybrid GAPDH molecule between
endogenous and Myc-tagged wild-type/C152-GAPDH was calcu-
lated based on band intensities obtained via Western blotting, us-
ing the anti-GAPDH monoclonal antibody. Detection was
performed using both SuperSignal West Pico Chemiluminescent
Substrate and HyperFilm according to the manufacturer's proce-
dure (GE Healthcare Japan). The band intensities were measured
using Scion imaging software. To detect insoluble GAPDH oligomers
in cells, the pellet obtained from the total cell lysate was then
resuspended in 200 ml of buffer B containing 10 mM HEPES-KOH
(pH 7.4), 25 mM NaCl, 3 mM MgCl2, 300 mM sucrose, 40 mM
iodoacetamide, 1 mM PMSF, and protease inhibitor mixture (Roche
Diagnostics), and washed 3 times by centrifugation (3000  g for
10 min), followed by suspension in buffer. After the addition of
100 ml of buffer B, the pellet was sonicated for 30 s and ﬁnally
obtained as the insoluble fraction. These fractions were stored
at 80 C until use. Protein concentrations of the samples were
determined by the Bradford assay (Bio-Rad Laboratories, Hercules,
CA). Both total lysates and fractionated proteins were mixed with
low SDS-sample buffer (ﬁnal concentration: 62.5 mM TriseHCl [pH
6.8], 0.5% SDS, 10% glycerol, 0.002% bromophenol blue) and then
heated at 100 C for 5min. These samples were separated by 5e20%
non-reducing SDS-PAGE and transferred to a nitrocellulose mem-
brane (Bio-Rad Laboratories). The membranes were incubated for1 h with Blocking One (Nacalai Tesque, Kyoto, Japan) to block
nonspeciﬁc binding. The membrane was then incubated for 2 h at
room temperature with an anti-GAPDH monoclonal antibody
(1:300) or an anti-b-actin monoclonal antibody (1:4000) in 10%
Blocking One-PBST (0.05% Tween 20, and 0.02% NaN3 in PBS), fol-
lowed by incubation for 1 h at room temperature with peroxidase-
conjugated afﬁnity-puriﬁed secondary antibody (Invitrogen).
Detection of insoluble GAPDH oligomers was performed using both
SuperSignal West Pico Chemiluminescent Substrate (GE Healthcare
Japan) and LAS3000 (FUJI-FILM, Tokyo, Japan). The intensity of the
bands was measured using Multi Gauge V3.0 (FUJI-FILM).2.7. Cell immunoﬂuorescence
We performed immunoﬂuorescence as described previously
[6,7]. The cells were then incubated overnight at 4 C with an anti-
GAPDH polyclonal antibody (1:1000) in 10% Blocking One-PBST.
After washing four times with PBST, speciﬁc signals were visual-
ized by staining the cells with an Alexa568-conjugated secondary
antibody (1:2000, Invitrogen) using a confocal scanning micro-
scope (C1si-TE2000-E; Nikon, Tokyo, Japan). For semi-
quantiﬁcation of cells with aggregates, ﬁve microscopic ﬁelds
were selected at random, and the number of cells with aggregates
among at least 500 total cells was quantiﬁed as a percentage [7].
Fig. 4. C152A-GAPDH inhibits NO-induced GAPDH amyloidogenesis. (A) The effect of C152A-GAPDH (0.75 mg/ml) on NOR3 (100 mM for 24 h at 37 C)-induced amyloid formation
by WT-GAPDH (0.3 mg/ml) is shown. Thioﬂavin-T binding-dependent ﬂuorescence of recombinant GAPDH treated with NOR3 is shown (n ¼ 3, **, p < 0.01). (B) The absorbance
spectra of Congo Red are shown. WT- and C152A-GAPDH were mixed and treated with NOR3. After incubation, Congo Red solution was added, and the absorbance of the ﬁnal
solution was measured. (C) Morphological analysis of recombinant GAPDH mixtures (WT and WT plus C152A) treated with NOR3 by AFM is shown. Scale bar ¼ 0.5 mm.
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Cytotoxicity was measured in terms of cell viability using the
Cell Titer Glo Luminescent Cell Viability Assay kit (Promega, Mad-
ison, WI) according to the manufacturer's protocol [7].
2.9. Docking simulation of GAPDH heterotetramer composed of a
dimer of wild-type and a dimer of C152A-GAPDH
Structural model of a GAPDH heterotetramer, formed from a
dimer of human wild-type GAPDH (PDB code 1U8F) and a dimer of
C152A-GAPDH, generated by ZDOCK version 3.0.2 [24].
2.10. Statistical analysis
All data represent the mean ± S.D. of independent experiments,
with the number of repeats (n) indicated in each Figure legend. For
statistical analysis, two groups andmultiple groups were compared
using the unpaired Student's t test or Dunnet's multiple test after
one-way analysis of variance (ANOVA), respectively (GraphPad
Prism ver. 6.01, GraphPad Software, Inc., CA).
3. Results and discussion
We previously reported that the C152A-GAPDH mutant, which
contained an alanine substituted at the site of the active site
cysteine residue responsible for GAPDH aggregation, lacked its
aggregation property under oxidative/nitrosative stress conditions
[7]. Therefore, we ﬁrst tested how C152A-GAPDH inﬂuences nitricoxide (NO)-induced wild-type (WT)-GAPDH aggregation in vitro
(Fig. 1). Treatment of His-tagged WT-GAPDH (0.3 mg/ml) with
NOR3, a NO generator, resulted in an increase in the turbidity of the
solution, i.e., GAPDH aggregation (Fig. 1, white circles). Pre-
incubation of WT-GAPDH with C152A-GAPDH (0.3, 0.6, or
0.75mg/ml) ameliorated NOR3-inducedWT-GAPDH aggregation in
a concentration-dependent manner (Fig. 1, right panel, black
symbols). This inhibitory effect was seen only following pre-
incubation of these mixtures (Fig. 1, right panel), indicating the
conversion of the oligomeric status of the WT-/C152A-GAPDH
tetramer, dimer, and monomer at equilibrium. These results sug-
gest hybridization between WT-GAPDH and C152A-GAPDH.
GAPDH variants derived from different species easily form hybrid
tetramers [18]. Therefore, we conﬁrmed whether native GAPDH
(corresponding to WT-GAPDH) is able to hybridize His-tagged
C152A-GAPDH by an immunoprecipitation assay using an anti-
His antibody (Fig. 2). Under conditions of pre-incubation of native
GAPDH (0.3 mg/ml) with His-tagged C152A-GAPDH (0.75 mg/ml),
native GAPDHwas co-immunoprecipitatedwith His-tagged C152A-
GAPDH (Fig. 2A), indicating that each WT-GAPDH molecule within
tetramer can hybridize with C152A-GAPDH protein subunits. To
further address the stoichiometry of hybridization between WT-
and C152A-GAPDH, we performed the co-immunoprecipitation
assay using WT-GAPDH (0.3 mg/ml) pre-incubated with different
amounts of C152A-GAPDH (0.3, 0.6, or 0.75 mg/ml, Fig. 2B). The
ratio of co-immunoprecipitated native GAPDH and His-tagged
C152A-GAPD was approximately 1:1 in all of concentrations of
C152A-GAPDH (Fig. 2B, right panel). Thus, C152A-GAPDH appears
to interfere with NOR3-induced WT-GAPDH aggregation through
Fig. 5. Expression of C152A-GAPDH inhibits the formation of GAPDH aggregates in SH-SY5Y cells. (A) Hybrid formation of endogenous GAPDH and induced-GAPDH in
doxycycline (DOX)-inducible GAPDH cells is shown. Bars indicate the ratio of induced/endogenous GAPDH (n ¼ 3). (B) NOC18 (200 mM)-induced GAPDH aggregates in the insoluble
fraction of DOX-inducible SH-SY5Y cells are shown. The bars indicate the semi-quantiﬁcation of band intensities of the GAPDH aggregates (described as oligomers) (n ¼ 3, *,
p < 0.05; **, p < 0.01). The blots of b-actin are used for a loading control. (C) Fluorescence of total GAPDH (red) in WT- and C152A-GAPDH inducible cells without () or with (þ)
DOX treated with NOC18 (200 mM, 48 h) is shown. The arrows indicate GAPDH aggregates. The numbers of cells with GAPDH aggregates were measured (right panel, n ¼ 5, **,
p < 0.01). Scale bar ¼ 10 mm.
T. Kubo et al. / Nitric Oxide 53 (2016) 13e2118the formation of the hybrid tetramer consisting of equal number of
each subunit. Further, the addition of the same molar amount of
other cysteine-containing glycolytic enzymes of alcohol dehydro-
genase (ADH), malate dehydrogenase (MDH), or aldolase (ALD),
which are lacking the property of NO-induced aggregation [5], did
not inhibit GAPDH aggregation (Fig. 3A). We next investigated ef-
fect of its substrate glyceraldehyde-3-phosphate (GAP) on NO-
induced GAPDH aggregation because GAP binds to Cys-152 to
form a thiohemiacetal intermediate during the glycolytic reaction
[20] (Fig. 3B). GAP did not affect NO-induced GAPDH aggregation(Fig. 3B). Further, high concentrations (1e10 mM) of glutathione
(GSH), which are abundantly present in cells as an endogenous
anti-oxidant, rather augmented NO-induced GAPDH aggregation
(Fig. 3C). Together, these results suggest that the C152A-GAPDH
molecule is a speciﬁc dominant-negative mutant against NO-
induced GAPDH aggregation.
We next examined whether C152A-GAPDH affected the NO-
induced amyloidal characteristics of WT-GAPDH aggregates
(Fig. 4). Co-incubation of WT-GAPDH with C152A-GAPDH resulted
in no ﬂuorescence from the amyloid-binding dye Thioﬂavin-T
Fig. 6. NO-induced cell death is restored by C152A-GAPDH expression. Effect of 48-h
incubation with NOC18 (100, 150, or 200 mM) on the cell viabilities of WT- (left panel)
and C152A- (right panel) inducible cells without () or with (þ) DOX treatment is
shown (n ¼ 3e4 *, p < 0.05, **, p < 0.01).
T. Kubo et al. / Nitric Oxide 53 (2016) 13e21 19(Fig. 4A). Numerous amyloid proteins exhibit an inherent spectral
shift upon incubation with an amyloid dye Congo Red from
approximate 500 nm to about 540 nm [25]. Although treatment of
NOR3 with WT-GAPDH consistently shifted the peak of the Congo
Red spectrum from 505.2 nm to 530.4 nm (Fig. 4B, left panel), co-
incubation with C152A-GAPDH inhibited the spectral shift even in
the presence of NOR3 (wavelength of maximal ﬂuorescence emis-
sion for WT-GAPDH ¼ 499.8 nm, WT-GAPDH plus C152A-
GAPDH ¼ 500.4 nm; Fig. 4B, right panel). Moreover, morphological
analysis using an atomic forcemicroscope (AFM) revealed that ﬁbrilFig. 7. Simulation of GAPDH-heterotetramer of the human WT-GAPDH dimer to a
(PDB number: 1U8F) is shown. (B) A docking model of GAPDH-heterotetramer of the
shown. The simulation was performed by ZDOCK Version 3.0.2. The active site Cysteine
colored as orange.structure formation byWT-GAPDHwas inhibited by the addition of
C152A-GAPDH under NOR3-treatment (Fig. 4C). Thus, C152A-
GAPDH is also likely to act as a speciﬁc dominant-negative
mutant against the amyloid-like characteristics of NO-induced
GAPDH aggregates.
To further investigate the dominant-negative effect of C152A-
GAPDH in cells, we examined whether the overexpression of
C152A-GAPDH in doxycycline (DOX)-inducible SH-SY5Y cells
resulted in the formation of a hybrid with endogenous GAPDH.
Similar to the results in Fig. 1, we conﬁrmed that both Myc-tagged
WT and C152A-GAPDH induced by Dox hybridized with endoge-
nous GAPDH in cells in an immunoprecipitation assay using an
anti-Myc antibody (Fig. 5A, left panel). The ratio of co-
immunoprecipitated endogenous GAPDH and Myc-tagged WT/
C152A-GAPDH was approximately 1:1 (Fig. 5A, right panel), similar
to the results obtained from puriﬁed GAPDH (Fig. 2B). Then,
Western blot analysis showed that the levels of DOX-induced plus
endogenous aggregated GAPDH oligomers induced by NOC18 (a NO
generator, 200 mM) in insoluble fractions were signiﬁcantly
augmented by WT-GAPDH overexpression (Fig. 5B). Consistently,
the overexpression of C152A-GAPDH extensively ameliorated
NOC18-induced endogenous GAPDH aggregation (Fig. 5B). Under
these conditions, we assessed the levels of cells with total GAPDH
aggregates, which were concomitant with the levels of insoluble
GAPDH oligomers obtained from Western blot analysis (Fig. 5B).
Similar results were assessed by a cell immunoﬂuorescence anal-
ysis (Fig. 5C). These results support the in vitro study (Figs. 1 and 2),
which showed that the presence of the C152A-GAPDH dominant-dimer of human C152A-GAPDH. (A) Structure of human GAPDH-homotetramer
human WT-GAPDH dimer (silver) to a dimer of human C152A-GAPDH (green) is
-152 in WT-GAPDH and Alanine-152 substituted for Cysteine in C152A-GAPDH are
T. Kubo et al. / Nitric Oxide 53 (2016) 13e2120negative mutant interferes with NO-induced GAPDH aggregation
via the formation of a hybrid molecule with endogenous GAPDH.
To clarify the linkage between levels of GAPDH aggregation and
NO-induced cell death, we investigated the effect of overexpression
of WT- and C152A-GAPDH on NOC18-induced cell death (Fig. 6). In
agreement with our previous ﬁndings using dopamine as an
oxidative/nitrosative stressor [6,7], signiﬁcant augmentation of cell
death was observed in inducible cells overexpressing WT-GAPDH
(Fig. 6, left panel). Conversely, prominent protection by over-
expression of C152A-GAPDH was observed under NOC18-
treatment (Fig. 6, right panel). Hence, NOC18-induced cell death
is likely to correlate with the levels of GAPDH aggregation in each
inducible cell, suggesting the disturbance of endogenous GAPDH
aggregation by the formation of a hybrid molecule with C152A-
GAPDH.
In the present study, we identiﬁed that C152A-GAPDH acts as a
dominant-negative mutant against GAPDH aggregation and pro-
vides protection against cell death under exposure to nitrosative
stress. We previously reported that the overexpression of C152A-
GAPDH in SH-SY5Y has no-inﬂuence on cellular glycolytic activity
[7]. In this context, we also found that NO-induced GAPDH aggre-
gation in cells is not impacted by glucose concentrations in culture
medium (data not shown); cellular event of GAPDH aggregates
formation under nitrosative stress is not related to glycolysis. Thus,
the dominant-negative effect of C152A-GAPDH is purely dependent
on the formation of the hybrid GAPDH molecule, leading to inter-
ference of GAPDH aggregation-induced cell death. Human GAPDH
is a homotetramer best described as a dimer of dimers (Fig. 7A)
[16,17]. Also, heteromeric hybridization of GAPDH dimer, e.g., a
heterotetramer derived from various monomeric species, is formed
easily [18,19]. Indeed, immunoprecipitation assays in this study
demonstrate the formation of hybrid GAPDH, consisting of native
GAPDH and His-tagged recombinant WT-GAPDH, or cellular
endogenous GAPDH and Myc-tagged recombinant WT-/C152A-
GAPDH (Figs. 2 and 5). Additionally, GAPDH dimers can form
distinct heterotetramers by associating with dimers of another
enzyme [26,27]. Further, a docking model of the human WT-
GAPDH dimer to a dimer of human C152A-GAPDH conﬁrmed that
this interaction is possible (Fig. 7B). These ﬁndings strongly indicate
the formation of heterotetramer at equilibrium of the presence of
each GAPDH tetramer, dimer, and monomer. Therefore, C152A-
GAPDH might function as a dominant-negative molecule against
both GAPDH aggregation and GAPDH-induced cell death through
the formation of a heterotetramer with the aggregation-proneWT-
GAPDH. This hypothesis provides a new potential therapeutic
strategy for some neurological disorders related to GAPDH aggre-
gation. In this regard, further in vivo study and analyses of the
beneﬁcial characteristics of C152A-GAPDH are needed. Currently,
we have generated a conditional C152A-GAPDH transgenic mouse;
this genetically modiﬁed mouse exerts robust neuroprotective ef-
fects on oxidative/nitrosative stress-triggered brain damage
induced by middle cerebral artery occlusion (MCAO) in mice stroke
model (unpublished data). Thus, the ﬁndings in this study, in
particular the molecular mechanism underlying possible
combating cell death utilizing by C152A-GAPDH, form the basis of
therapeutic applications, in which we are investigating in vivo-
study.
4. Conclusion
The present study shows that C152A-GAPDH acts as a
dominant-negative mutant, protecting against GAPDH
aggregation-induced cell death through the formation of the hybrid
heterotetramer between GAPDH and C152A-GAPDH. This interfer-
ence strategy may offer a novel insight into the therapeuticsigniﬁcance of mutant GAPDH in neurodegenerative/neuropsychi-
atric disorders that are accompanied by GAPDH aggregate
formation.
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